Meera Mohan

Dr. Meera Mohan

Medical College of Wisconsin, Milwaukee, WI 53226, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2024 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
MMMeera Mohan
Meera Mohan
JMJorge Monge
Jorge Monge
NSNishi Shah
Nishi Shah
DLDanny Luan
Danny Luan
MFMark Forsberg
Mark Forsberg
RCRajshekhar Chakraborty
Rajshekhar Chakraborty
The objective of our study was to report real-world data on the safety and efficacy of standard-of-care teclistamab in patients with relapsed/refractory multiple myeloma (MM). This is a multi-institutional retrospective cohort study and included all consecutive patients that received at least one dose of teclistamab up until August 2023. One hundred and ten patients were included, of whom, 86% had triple-class refractory disease, 76% penta-refractory disease, and 35% had prior exposure to B-cell maturation antigen (BCMA)-targeting therapies. The overall response rate (ORR) in our cohort was 62%, with a ≥ very good partial remission (VGPR) rate of 51%. The ORR in patients with and without prior BCMA-targeted therapies was 54% vs 67%, respectively (p = 0.23). At a median follow-up of 3.5 months (range, 0.39–10.92), the estimated 3 month and 6 month progression free survival (PFS) was 57% (95% CI, 48%, 68%) and 52% (95% CI, 42%, 64%) respectively. The incidence of cytokine release syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS) was 56% and 11% respectively, with grade ≥3 CRS and ICANS noted in 3.5% and 4.6% of patients respectively. 78 unique infections were diagnosed in 44 patients, with the incidence of all-grade and grade ≥3 infections being 40% vs 26% respectively. Primary prophylaxis with intravenous immunoglobulin (IVIG) was associated with a significantly lower infection risk on multivariate analysis (Hazard ratio [HR] 0.33; 95% CI 0.17, 0.64; p = 0.001).

7 June 2023 in British Journal of Haematology
Verified
Journal Article
Open access
MMMeera Mohan
Meera Mohan
RCRajshekhar Chakraborty
Rajshekhar Chakraborty
SBSusan Bal
Susan Bal
ANAnoma Nellore
Anoma Nellore
MBMuhamed Baljevic
Muhamed Baljevic
LCLuciano J. Costa
Luciano J. Costa
Summary: Chimeric antigen receptor T (CAR T) cell and bispecific antibody therapies have shown unprecedented efficacy in heavily pretreated patients with multiple myeloma (MM). However, their use is associated with a significant risk of severe infections, which can be attributed to various factors such as hypogammaglobulinemia, neutropenia, lymphopenia, T‐cell exhaustion, cytokine‐release syndrome and immune‐effector cell‐associated neurotoxicity syndrome. As these therapies have been recently approved by regulatory agencies, it is crucial to establish practical guidelines for infection monitoring and prevention until robust data from prospective clinical trials become available. To address this issue, a panel of experienced investigators from the Academic Consortium to Overcome Multiple Myeloma through Innovative Trials (COMMIT) developed consensus recommendations for mitigating infections associated with CAR T‐cell and bispecific antibody therapies in MM patients.

18 April 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
MMMeera Mohan
Meera Mohan
SNSneha Nagavally
Sneha Nagavally
BDBinod Dhakal
Binod Dhakal
SRSabarinath Venniyil Radhakrishnan
Sabarinath Venniyil Radhakrishnan
SCSaurabh Chhabra
Saurabh Chhabra
PHParameswaran Hari
Parameswaran Hari
Meera Mohan, Sneha Nagavally, Binod Dhakal, Sabarinath Venniyil Radhakrishnan, Saurabh Chhabra, Anita D'Souza, Parameswaran Hari; Risk of infections with B cell

24 February 2022 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
JDJing Dong
Jing Dong
ZGZhuping Garacci
Zhuping Garacci
CBChristopher Staffi Buradagunta
Christopher Staffi Buradagunta
ADAnita D’sOuza
Anita D’sOuza
MMMeera Mohan
Meera Mohan
PHParameswaran Hari
Parameswaran Hari
We assessed differences in survival between non-Hispanic black (NHB) and non-Hispanic white (NHW) patients with multiple myeloma (MM), and the sequential effects of patient characteristics, and diagnosis and treatment-related factors on the survival disparity using data from 3319 NHB and 20,831 NHW MM patients in the SEER-Medicare (1999–2017) database. Four sets of 3319 NHWs were matched sequentially to the same set of 3319 NHBs, based on demographics (age, sex, year of diagnosis, marital status, and SEER site), socioeconomic status (SES, demographics plus SES), presentation factors (SES variables plus comorbidity), and treatment factors (presentation variables plus antimyeloma therapies). We found NHBs were less likely to receive treatment than NHWs even among patients matched for demographics, SES, and comorbidities. The absolute difference in 5-year survival between NHBs and NHWs was not significant in the demographics match (0.6%; P = 0.30) and remained non-significant after matching for SES (1.4%, P = 0.17). When matching for presentation, NHBs had significantly longer 5-year survival than NHWs (absolute difference = 3.8%, P = 0.003). Additional matching on treatment-related factors further enlarged the racial difference in 5-year survival to 4.6% (P < 0.001). Our findings reinforce the importance of equitable access to effective treatment modalities to further improve the survival of NHB patients with MM.

23 April 2025 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
MMMeera Mohan
Meera Mohan
ASAniko Szabo
Aniko Szabo
HCHeloise Cheruvalath
Heloise Cheruvalath
ACAnna Clennon
Anna Clennon
VBVineel Bhatlapenumarthi
Vineel Bhatlapenumarthi
CSCarolina Schinke
Carolina Schinke
The main objective of this multi-institutional study is to understand the effect of primary intravenous immunoglobulin (IVIG) replacement on clinical outcomes in recipients of BCMA-directed bispecific antibody (bsAb), where infection remains an important cause of morbidity and mortality. This is a retrospective study of patients treated with either standard of care teclistamab or BCMA-directed investigational bsAb between Nov 2017 and Dec 2023. Primary IVIG prophylaxis was defined as starting IVIG prior to first documented infection. All analyses were adjusted for immortal-time bias inherent in this grouping. A total of 225 patients were included in this analysis. Primary IVIG prophylaxis was defined as starting IVIG prior to first documented infection. The median follow-up of patients treated with and without primary IVIG prophylaxis was, 9 and 11 months, respectively. The cumulative incidence of all grade infections at 12 months with and without primary IVIG prophylaxis were 56% (95%CI 40%,78%) and 60% (95% CI 48%, 76%); p = 0.72, respectively. The 12-month cumulative incidence of ≥ grade 3 infections was 35% (95% CI 21%, 57%) with primary IVIG prophylaxis and 45% (95% CI 34%, 60%) without; p = 0.37. The median infection free survival (IFS) for all-grade infections was 7.7 (95% CI 3.3, 14) months with primary IVIG prophylaxis and 3 (95% CI 2.6, 4.5) months without (p = 0.021). The median ≥ grade 3 IFS was 14 (95% CI 8.8, NR) and 7.5 (95% CI 6.1, 14) months, with and without primary IVIG respectively; p = 0.022. Patients on primary IVIG prophylaxis had a superior progression-free-survival (PFS) [median PFS 15 vs 8 months; p = 0.026] and overall-survival (OS) [median OS 16 vs 44 months; p = 0.007]. On multivariate analysis, primary IVIG prophylaxis was independently associated with improved OS (HR = 0.37; p = 0.021), while the presence of extra-medullary (HR = 2.71; p = <0.001) and high-risk disease (HR = 1.88; p = 0.031) conferred poor outcomes. In recipients of BCMA-directed bsAb, IVIG supplementation was associated with an improved clinical outcome, including favorable IFS and OS.

28 October 2022 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
LHLindsay R. Hammons
Lindsay R. Hammons
ASAniko Szabo
Aniko Szabo
AJAbhishek Janardan
Abhishek Janardan
BDBinod Dhakal
Binod Dhakal
SCSaurabh Chhabra
Saurabh Chhabra
MMMeera Mohan
Meera Mohan
Bispecific antibodies (bsAb) targeting novel antigens are a promising class of therapeutics for relapsed refractory multiple myeloma (RRMM).1,2 Although hypogammaglobulinemia is expected due to plasma cell depletion,3-5 little is known regarding the degree of humoral immunodeficiency and infectious complications with bsAb. We report on the kinetics of humoral deficiency among patients with RRMM treated with bsAb, the infectious complications, and response to COVID-19 immunization.